AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05702775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment group (EUS-GBD group
Description: The placement of a endoscopic drain performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy. Subsequently, the interior of the gallbladder will be irrigated with saline solution until the vesicular content comes out.
Study NCT05327049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: treatment of deep carious lesions
Study NCT05327049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: laser light for cavity disinfection
Study NCT05327049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe Vera
Description: herbal dietary supplement for treatment of deep carious lesions
Study NCT04810260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use mobile health app (WellXcel) to increase knowledge
Description: Download the app (WellXcel) to the mobile device
Study NCT05896774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept
Description: Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.
Study NCT05664334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-121
Description: 75 mcg of IVX-121 without MF59®
Study NCT06104241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGT007 Injection
Description: BGT007 injection (d0) were infused intravenously once, and the dose group was 5.0× 10\^7 cells,1.0 ×10\^8 cells, 3.0× 10\^8 cells,1.0 × 10\^9 cells,3.0 ×10\^9 cells.
Study NCT05142098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intramuscular
Study NCT05142098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Description: Orally
Study NCT06233084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel-Test product
Description: Desogestrel Tablets 0.075 mg Manufactured by: POND'S CHEMICAL THAILAND R.O.P., Thailand
Study NCT06233084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel-Reference product
Description: Desogestrel Tablets 0.075 mg Manufactured by: N.V. Organon, The Netherlands
Study NCT05040646 — intervention group
Intervention type: OTHER
Intervention: Delphi exercise
Description: During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W\&W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item.~After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached.
Study NCT05038696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Description: This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.
Study NCT05007314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biocriminological Evidence
Description: Participants in each of the two main groups see a case with and a case without a neurobiological explanation for criminal offending.
Study NCT05007314 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biocriminological Evidence
Description: Participants in each of the two main groups see a case with and a case without a neurobiological explanation for criminal offending.
Study NCT04860050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmipure Gold®
Description: TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
Study NCT04860050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: colored acacia gum - 1 capsule per day - as prescribed
Study NCT05097417 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine and ablation in the primary tumor sites
Description: Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
Study NCT05664334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-241
Description: 75 mcg of IVX-241 without MF59®
Study NCT05664334 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent
Study NCT05097417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: Patients will be treated with ablation in the primary tumor sites
Study NCT05664334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-121
Description: 75 mcg of IVX-121, without MF59®
Study NCT05504512 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05531500 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Injection
Description: Injection of local anesthetic + steroids
Study NCT05531500 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency
Description: Application of radiofrequency on the diseased nerve
Study NCT05664334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-241
Description: 150 mcg IVX-241, without MF59®
Study NCT05664334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-241
Description: 225 mcg of IVX-241, without MF59®
Study NCT05664334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-121
Description: 75 mcg of IVX-121, with MF59®
Study NCT05664334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-241
Description: 75 mcg of IVX-241, with MF59®
Study NCT05664334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-241
Description: 150 mcg IVX-241, with MF59®
Study NCT05664334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MF59®
Description: MF59® as an adjuvant
Study NCT06177444 — intervention group
Intervention type: DRUG
Intervention: Antibiotic
Description: Postoperative antibiotic treatment
Study NCT05633719 — intervention group
Intervention type: OTHER
Intervention: Chemotherapy involving cisplatin or carboplatin
Description: Chemotherapy
Study NCT06522958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dissolving Transitional Food
Description: Transitional foods are solid foods that rapidly change texture in the presence of moisture (e.g., water or saliva) or temperature change. Duration of consumption of the investigational agent will include the time of the surgery until the second post-operative evaluation. This is estimated to be approximately 1-2 months in total.
Study NCT05464316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Transobturator Male System
Description: The ATOMS sling was developed in 2008 by Agency for Medical Innovations GmbH in Austria. It is a self-anchoring adjustable system which supports the bulbar urethra dorsally and uses the trans obturator approach. This device gained its fame in the male sling scene by being adjustable, which theoretically makes it more efficacious than its competitors.
Study NCT05464316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Urinary Sphincter
Description: The AMS800™, which is by far the most frequently implanted AUS, was first marketed in 1983 and was developed by America Medical Holdings in Minnesota. Today, the AUS has been given the title gold standard for surgical treatment for PPI. This device is an inflatable cuff which wraps around the urethra to supply circumferential pressure. It has a control pump, which is found in the scrotum and is operated by the patient. The patient can void simply by squeezing the pump, which brings the fluid from the cuff to a reservoir and release the pressure around the urethra. The cuff is then automatically refilled with fluid within a couple of minutes to close back the sphincter.
Study NCT06411743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Albumin Injection
Description: Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.
Study NCT06411743 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Albumin
Description: Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.
Study NCT05861193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment of the abfraction with BOPT technique
Description: The steps to follow for the treatment of abfraction using composite resin and the B.O.P.T. technique will consist of:~* Selection of the color of the composite, placement of the retraction cord and chamfering of the coronal margin of the lesion;~* Application of 37% phosphoric acid etching and adhesive in 3 steps; placement of the composite by layers, following the conventional obturation technique.~* Execution of an overfilling with the composite at the level of the cervical emergence profile of the tooth, with the aim of emphasizing said anatomical particularity.~* Removal of the retraction cord.~* Diamond milling with red rim flame diamond bur and contra-angle, positioned from the most apical point of the restoration at an angle of 45º without touching the restored dental portion, with the aim of performing a level rotary gingival curettage from the margin of the restoration.~* Polishing with a fine-grain flame bur, and polishing discs of decreasing granulometry.
Study NCT06133049 — intervention group
Intervention type: DRUG
Intervention: Ozanimod
Description: Women with MS who were exposed to ozanimod during pregnancy
Study NCT06133049 — intervention group
Intervention type: DRUG
Intervention: Select DMTs other than ozanimod
Description: Women with MS exposed to select DMTs other than ozanimod during pregnancy
Study NCT06133049 — intervention group
Intervention type: DRUG
Intervention: No DMTs
Description: Women with MS not exposed to any DMTs during pregnancy
Study NCT06303492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GUS
Description: Aspiration risk assessment by GUS
Study NCT05368831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-1024
Description: Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
Study NCT05330234 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OnTrack Tools
Description: The intervention is the OnTrack Tools system consisting of a graphical user interface (GUI) used to manage patients who are users of the OnTrack rehabilitation system. Participants will be asked to complete clinical and non-clinical tasks in simulation using OnTrack Tools. The themes for the scenarios of use presented in each of the three phases are summarised below:~Phase 1 - Account creation, system onboarding and general system navigation. Phase 2 - Individual patient management. Phase 3 - Content and data management.
Study NCT06205394 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06257537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 2.5% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
Study NCT06257537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Acoustic Device with 0% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
Study NCT06257537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% Diclofenac Patches
Description: Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
Study NCT06257537 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SAM Patch
Description: Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.
Study NCT05229835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating and exercise
Description: We apply time restricted eating, exercise alone and combined
Study NCT05952258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic stimulation
Description: The magnetic stimulation to the pelvic floor muscle will be provided by the Emsella® chair: which will be activated for 28 minutes at each treatment session. The treatment arm will receive up to 100% intensity at each treatment session.
Study NCT05952258 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Magnetic stimulation
Description: The sham arm will receive up to 5% intensity at each treatment session
Study NCT05175274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5mg/tablet
Study NCT05175274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT06199232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+targeted therapy+PD-1 inhibitor
Description: HAIC regimen: doublet or triplet regimen based on the response and adverse events occurred in the previous standard treatment (depended on the decision of researchers)-oxaliplatin (85 mg/m2, split into d1 and d2, 0-2h,) and 5-fluorouracial (2g/m2, split into d1 and d2, 2-24h)/ oxaliplatin (65 mg/m2, 0-2h, d1), irinotecan (100 mg/m2, 0-2h, d2), and 5-fluorouracial (2g/m2, split in d1 and d2, 2-24h), repeated every 4 weeks; drug-eluting TACE will be performed at 3rd-4th cycles if the lesions in liver is abundant with blood supply.~Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.~Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.~Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w.
Study NCT04684368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of CSF and blood samples
Study NCT04684368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04684368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT04684368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously (SC) or IV
Study NCT04684368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT04684368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04684368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV or orally
Study NCT04684368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT04684368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplant
Study NCT04684368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04684368 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo WVSCI radiation therapy
Study NCT04684368 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04684368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second-Look Surgery
Description: Undergo second-look surgery if needed
Study NCT04684368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT06049173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative extra-abdominal pressure (NEXAP)-based lung recruitment maneuver
Description: The ventilator mode was changed from SIMV to PSV before LRM. After that, the abdominal pressure cardiopulmonary resuscitation (CPR-LW100) instrument was adopted and adsorbed on the epigastrium of patients. The LRM was performed by pulling up (tension of 20-30 kg) and compressing downward (tension\<10 kg) alternately on the abdomen of the patients with a frequency of 12 times per minute to support and maintain breathing. The whole LRM procedure lasted for 3 minutes in total. After LRM, the ventilator mode was changed to its baseline settings.
Study NCT06049173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stepwise positive end-expiratory pressure (PEEP)-based lung recruitment maneuver
Description: The ventilator mode was changed from SIMV to PSV before LRM. After that, PEEP was increased gradually (every 3-5cmH2O per 30s) from baseline (5-8 cmH2O) to 20cmH2O. The PEEP level was maintained at 20cmH2O for 60s, followed by decrements to baseline PEEP (every 3-5cmH2O per 30s). After LRM, the ventilator was changed to the baseline settings.
Study NCT05289752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental implants in the mandible
Description: placement of two interforaminal dental implants in the canine region in the mandible
Study NCT05289752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: locator attachment and overdenture
Description: placement of locator attachment and insertion of mandibular overdenture
Study NCT06289868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
Description: Samples will be tested by comparing Access anti-HAV assay results to final anti-HAV sample status, and Access anti-HAV IgM results to final anti-HAV IgM status, according to respective instructions for use (IFU) or study guide, as applicable, to determine to determine non-reactive (NR), reactive (R), Negative, Positive or Equivocal (EQ).~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT).~For evaluation of the clinical performance of Access anti-HAV IgM assay, all clinical samples, except pre- and post-vaccinated patient samples, will be tested with the reference assays Abbott - ARCHITECT® HAVAb-IgM, DiaSorin - LIAISON® Anti-HAV IgM, and SIEMENS Healthineers Atellica IM® Hepatitis A IgM (aHAVM).
Study NCT06289868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
Description: All samples will be tested pre- and post-vaccination by comparing Access anti-HAV assay results to final anti-HAV status, according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity.~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT).
Study NCT04960124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
Study NCT06086964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic diet.
Description: gluten and casein free diet.
Study NCT06086964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: specific physiotherapy developmental program according to the pre evaluation of gross motor status.
Study NCT06151626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual-reality based rhythmic skill training
Description: Participants wear VR headsets and Oculus Touch controllers and undergo rhythm skill training for a total of 35 minutes.
Study NCT06151626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rhythmic skill training with visual feedback
Description: The rhythm skill training activities in this group are the same as the virtual reality-based system. Participants received 35 minutes of rhythm skill training presented through a computer interface
Study NCT06151626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strengthening group
Description: Participants receive an upper limb strengthening exercise program under the supervision of a therapist to ensure that the strengthening exercises are performed correctly. This includes: proprioceptive neuromuscular facilitation, resistance training, and tendon gliding exercises.
Study NCT06151626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breathing and muscle relaxation exercises
Description: 5 minutes of breathing and muscle relaxation exercises